Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma.

Jhawer, Minaxi; Rosen, Lee; Dancey, Janet; Hochster, Howard; Hamburg, Solomon; Tempero, Margaret; Clendeninn, Neil; Mani, Sridhar

Jhawer, Minaxi; Rosen, Lee; Dancey, Janet; Hochster, Howard; Hamburg, Solomon; Tempero, Margaret; Clendeninn, Neil; Mani, Sridhar.

Affiliation

Jhawer M; Montefiore Medical Center, NY, USA. mjhawer@montefiore.org

Invest New Drugs ; 25(1): 85-94, 2007 Feb.

Article in En | MEDLINE | ID: mdl-16957834

Subject(s)

Carcinoma, Hepatocellular/drug therapy; Liver Neoplasms/drug therapy; Quinazolines/therapeutic use; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic/adverse effects; Antimetabolites, Antineoplastic/pharmacokinetics; Antimetabolites, Antineoplastic/therapeutic use; Carcinoma, Hepatocellular/pathology; Drug Administration Schedule; Exanthema/chemically induced; Female; Humans; Infusions, Intravenous; Liver Neoplasms/pathology; Male; Metabolic Clearance Rate; Middle Aged; Nausea/chemically induced; Quinazolines/blood; Quinazolines/pharmacokinetics; Stomatitis/chemically induced; Survival Analysis; Time Factors; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Hepatocellular / Liver Neoplasms Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links